What specific benefits of Sovaldi have been demonstrated in studies?

12 июля 2015, 20:51

The first investigation consisted of 327 formerly untreated patients who were infected with Hepatitis C virus including genotypes 1, 4, 5 or 6, and who were administered Sovaldi in combination with two other antiviral medicines, Peginterferon alfa and Ribavirin, during 12 weeks. In this investigation, 91% (this makes up 296 out of 327) of individuals monitored on negative for Hepatitis C 12 weeks after the completion of treatment.

The second investigation included 499 formerly untreated patients who experienced Hepatitis C of genotypes 2 or 3. In this investigation, patients administered Sovaldi with Ribavirin for 12 weeks were compared with patients given Peginterferon alfa and Ribavirin during 16 weeks. Treatment with Sovaldi was as absolutely effective (67% patients - 171 out of 256 – indicated negative tests) as Peginterferon-based treatment (67% of all patients - 162 out of 243).

The third investigation was carried out in 278 patients with genotypes 2 or 3 Hepatitis C virus who could not take because of different reasons or did not want to undergo treatment with Interferon. This investigation compared 12 weeks of treatment with Sovaldi and Ribavirin with placebo (usually prescribed more for the psychological benefit to the patient than for any physiological effect) and came to conclusion that 78% (161 out of 207) of individuals taking Sovaldi and Ribavirin showed negative results for Hepatitis C 12 weeks after the completion of treatment, while none of 71 patients using placebo were cleared off of the virus.

The fourth investigation was conducted in 201 patients with Hepatitis C virus (genotypes 2 or 3) who did not react to former treatment with Interferon or whose infections relapsed. This investigation compared Sovaldi and Ribavirin used within 12 weeks with Sovaldi and Ribavirin taken for 16 weeks. In this case, 50% (51 out of 103) of patients taking Sovaldi and Ribavirin for 12 weeks showed negative results for Hepatitis C, while 71 % (70 out of 98) of individuals treated for 16 weeks tested negative.

Extra carried out investigations demonstrated that Sovaldi in combination with Ribavirin reduced the evident risk of infection of the new liver with Hepatitis C virus in people going through transplantation, that Sovaldi is as well effective in patients co-infected with Hepatitis C and HIV, and that the results of patients with genotype 3 infection could be improved by prolonging treatment to 24 weeks.

www.hcvhelp.net

#Денис Объедкин #Общество #Новости

Подпишитесь

Четверг в Карелии: выстрел в голову и южный циклон

Вчера, 17:42

Стало известно, у жителей какого района Карелии чаще находят рак

Вчера, 10:05

Опубликован график выплат пенсий в Карелии за май 2024 года

Вчера, 09:39

Незаконный автосервис принимал клиентов в Петрозаводске

Вчера, 09:17

Синоптики спрогнозировали аномальную погоду на майские праздники в Карелии

Вчера, 08:04

Парфенчиков рассказал, будет ли салют в Петрозаводске на 9 Мая

Вчера, 07:43